



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 57/42, 59/64, 47/232, A61K 31/19		A1	(11) International Publication Number: WO 00/53562
			(43) International Publication Date: 14 September 2000 (14.09.00)

<p>(21) International Application Number: PCT/EP99/01467</p> <p>(22) International Filing Date: 8 March 1999 (08.03.99)</p> <p>(71) Applicant: F. HOFFMANN-LA-ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basle (CH).</p> <p>(72) Inventors: BOLLAG, Werner; Mythenstrasse 10, CH-4054 Basle (CH). KLAUS, Michael; Am Hellenrain 6, D-79576 Weil am Rhein (DE). MOHR, Peter; Benkenstrasse 26, CH-4054 Basle (CH). PANINA-BORDIGNON, Paola; Via Piolti de'Bianchi, 4, I-20129 Milan (IT). ROSENBERGER, Michael; 79 Arlington Avenue, North Caldwell, NJ 07006 (US). SINIGAGLIA, Francesco; Via Poma, 11, I-20129 Milan (IT).</p> <p>(74) Agent: KJELLSAA-BERGER, Hanny; Grenzacherstrasse 124, CH-4070 Basle (CH).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
--	---

(54) Title: **RETINOID ANTAGONISTS AND USE THEREOF**

(I)

(57) Abstract

The present invention relates to novel retinoid antagonists of the formula (I) wherein the dotted bond is optional; and, when the dotted bond is present, R¹ is lower alkyl and R² is hydrogen; and, when the dotted bond is absent, R¹ and R² taken together are methylene to form a cis-substituted cyclopropyl ring; R³ is hydroxy or lower alkoxy; R⁴ is alkyl or alkoxy; and R⁵ and R⁶ are, independently, a C₄₋₁₂ alkyl group or a mono- or polycyclic C₅₋₁₂-hydrocarbon group which are linked to the phenyl ring through a quaternary carbon atom, and pharmaceutically acceptable salts of carboxylic acids of formula (I); the use of retinoid antagonists, their pharmaceutically acceptable salts or pharmaceutically acceptable hydrolyzable esters, for the manufacture of a medicament for the treatment of T-helper cell type 2 (Th2)-mediated immune diseases, for the manufacture of a medicament for the treatment of osteoporosis and for use in the treatment of preneoplastic and neoplastic diseases.

B4

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Retinoid Antagonists and use thereof

Retinoids are a class of compounds structurally related to vitamin A, comprising natural and synthetic compounds. Retinoids have been found to be clinically useful in the treatment of dermatological and oncological diseases.


Retinoids with retinoid receptor agonistic activity have been shown to be active not only in model systems for the treatment of dermatological and oncological diseases but also in models for the treatment of T-helper cell type 1 (Th1)-mediated immune diseases. Retinoids with retinoid receptor agonistic activity are active in the treatment of adjuvant arthritis [Brinckerhoff et al., Science 221, 756-758 (1983)] and experimental allergic encephalomyelitis [Massacesi et al., J. Clin. Invest. 88, 1331-1337 (1991); Racke et al., J. Immunol. 154, 450-458 (1995)], animal models for rheumatoid arthritis and multiple sclerosis, respectively. Both diseases are considered to belong to Th1-mediated, immune diseases.

Experimentally, retinoids with retinoid receptor antagonistic activity (retinoid antagonists) are effective in counteracting many properties of retinoids with retinoid receptor agonistic activity (retinoid agonists) such as inhibition of cell proliferation, induction of cell differentiation, induction of apoptosis and inhibition of angiogenesis [Bollag et al., Int. J. Cancer 70, 470-472 (1997)]. Retinoid antagonists are also suppressing toxic side effects of retinoid agonists such as the signs and symptoms of the hypervitaminosis A syndrome and teratogenesis [Standeven et al., Toxicol. Appl. Pharmacol. 138, 169-175 (1996); Eckhardt and Schmitt, Toxicol. Letters 70, 299-308 (1994)]. Therefore, they may be useful clinically in preventing or treating adverse events caused by retinoid agonists.

Retinoid antagonists have been proposed for clinical use in prevention and therapy of retinoid-induced toxicity and side effects, particularly of the so-called hypervitaminosis A syndrome. Retinoid antagonists have also been proposed to be used in combination with retinoid receptor agonists or other nuclear receptor agonists for prevention and treatment of preneoplastic or neoplastic lesions, vitreo-retinopathy and retinal detachment. In addition, retinoid antagonists have been proposed for use as single agents, based on their

anti-proliferative effect, for treatment of certain neoplasms insensitive to retinoid receptor agonists [WO 97/09297].

In a first aspect, the present invention relates to novel retinoid antagonists. According to this particular aspect, the present invention relates to compounds of the formula I



wherein the dotted bond is optional; and, when the dotted bond is present, R¹ is lower alkyl and R² is hydrogen; and, when the dotted bond is absent, R¹ and R² taken together are methylene to form a cis-substituted cyclopropyl ring; R³ is hydroxy or lower alkoxy; R⁴ is alkyl or alkoxy; and R⁵ and R⁶ are, independently, a C₄-12 alkyl group or a mono- or polycyclic C₅-12-hydrocarbon group which are linked to the phenyl ring through a quaternary carbon atom,


and pharmaceutically acceptable salts of carboxylic acids of formula I.

As used herein the term „alkyl“ means straight-chain, branched or cyclic alkyl residues, in particular those containing from 1 to 12 carbon atoms, such as methyl, ethyl, propyl, isopropyl, t-butyl, decyl, dodecyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. The term „lower alkyl“ means alkyl groups containing from 1 to 7, preferably 1-4 carbon atoms. Most preferred lower alkyl groups are methyl and ethyl. Alkyl and alkoxy groups denoted by R⁴ preferably contain 1-8 carbon atoms, more preferably 1-4 carbon atoms. Particularly preferred group R⁴ are ethoxy and butoxy. Examples of C₄-12 alkyl groups represented by R⁵ or R⁶ are tert.-butyl, 1,1-dimethylpropyl, 1-methyl-1-ethylpropyl, 1-methyl-1-ethylhexyl and 1,1-dimethyldecyl. Of these groups, tert.-butyl is preferred. Examples of mono- or polycyclic hydrocarbon groups represented by R⁵ and R⁶ are 1-adamantyl and 1-methylcyclohexyl.

The compounds of formula I wherein R³ is hydroxy form salts with pharmaceutically acceptable bases such as alkali salts, e.g. Na and K-salts, and ammonium or substituted


ammonium salts such trimethylammonium salts which are within the scope of this invention.

In one embodiment, the invention comprises compounds of the formula I a



wherein R^1 is lower alkyl and R^3 to R^6 are as in formula I;
and pharmaceutically acceptable salts of carboxylic acids of formula Ia.

In another embodiment the invention comprises compounds of the formula:



wherein R^3 to R^6 are as in formula I;
and pharmaceutically acceptable salts of carboxylic acids of formula Ib.

The compounds of formula I wherein R^1 and R^2 taken together are methylene, may be present in pure enantiomeric form or as racemates. While formula Ib arbitrarily depicts a particular enantiomeric form it is to be understood that the invention also comprises the opposite enantiomers as well as the racemates.

Particularly preferred are compounds of the formula Ia wherein R^1 is methyl, R^4 is ethoxy or butoxy and R^5 and R^6 are tert.-butyl.

The compounds of formula I above bind specifically to Retinoid X Receptors (RXR), but do not activate them. Accordingly the compounds of this invention can be used to reduce or abolish adverse events induced in patients


with dermatological or oncological diseases. Experimental investigations on this subject are described in Examples 1-3.

In a second aspect, the present invention relates to the use of retinoid antagonists comprising retinoids with selective Retinoic Acid Receptor (RAR) antagonistic activity, Retinoid X Receptor (RXR) antagonistic activity or mixed RAR-RXR antagonistic activity, for the manufacture of a medicament for the treatment of T-helper cell type 2 (Th2)-mediated immune diseases such as immunoglobulin E (IgE)-mediated allergic diseases, or diseases mediated by the Th2-related cytokines, as well as to the use of said active substances for the treatment of such diseases.

In accordance with that aspect of the invention the term "retinoid antagonists" is used for retinoids or compounds with RAR, RXR or mixed RAR-RXR antagonistic activity. It includes compounds with receptor neutral antagonistic activity (neutral antagonists), receptor inverse agonistic activity (inverse agonists) and negative hormone activity (negative hormones) [Klein et al., J. biol. Chem. 271, 22692-22696 (1996)].

Thus, the term "retinoid antagonists" encompasses


a) RXR antagonists of the formula I given earlier herein, particularly those of the formula




wherein the dotted bond is optional; and, when the dotted bond is present, R¹ is methyl and R² is hydrogen; and, when the dotted bond is absent, R¹ and R² taken together are methylene to form a cis-substituted cyclopropyl ring; and R⁴¹ is C₁₋₄-alkoxy;

b) RAR α -antagonists of formulae


5




III



IV;



V; and




VI,

5 wherein R^7 is C₅-10-alkyl, and R^8 and R^9 independently of each other are hydrogen or fluorine;

such compounds being described in US patent no. 5 391 766 and J. Med. Chem. 1997, 40, 2445;


c) RAR α,β antagonists of formulae




10

VII;

6



VIII; and




IX,

wherein R^{10} is diamantyl, X is O or NH, R^{11} is phenyl or benzyl, and wherein optionally either ring A or ring B is present;

- 5 such compounds being described in Med. Chem. Res. 1991, 1, 220; Biochem. Biophys. Res. Com. 1997, 231, 243; J. Med. Chem. 1994, 37, 1508;


d) RAR β, γ antagonists of formula




X,

- 10 wherein R^{12} and R^{13} independently of each other hydroxy, C_{1-4} -alkoxy, optionally branched C_{1-5} -alkyl or adamantyl;
such compounds being described in J. Med. Chem. 1995, 38, 4993;

e) RAR γ antagonists of formulae




XI; and




XII

such compounds being described in Cancer Res. 1995, 55, 4446;

f) RAR α, β, γ antagonists of formulae




XIII;




5

XIV,



XV; and




XVI

wherein Y is -CH₂- or sulfur and Z is -CH= or nitrogen, and R¹⁴ is hydrogen or C₁₋₄-alkyl;

such compounds being described in J. Med. Chem. 1995, 38, 3163 and 4764; J. Biol. Chem. 1996, 271, 11897 and 22692;

5 g) RXR antagonists of formula



XVII;

wherein R¹⁵ is C₁₋₄-alkoxy;

such compounds being described in J. Med. Chem. 1996, 39, 3229; and Nature 1996, 383, 450,

as well as pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters of the compounds of formulae III to XVII.

In the scope of the present invention, the „pharmaceutically acceptable salts“ includes any salt chemically permissible in the art for retinoid antagonists and applicable to human patients in a pharmaceutically acceptable preparation. Any such conventional pharmaceutically acceptable salt of retinoid antagonists can be utilized. Among the conventional salts which can be utilized, there are the base salts included, for example, alkali metal salts such as the sodium or potassium salt, alkaline earth metal salts such as the calcium or magnesium salt, and ammonium or alkyl ammonium salts.

In accordance with this second aspect of the invention, it has thus been found that administration of retinoid antagonists, pharmaceutically acceptable salts, and pharmaceutically acceptable hydrolyzable esters thereof, are efficacious in treating patients with T-helper cell type 2 (Th2)-mediated diseases. It has also been found that the administration of retinoid antagonists is efficacious in treating patients with diseases mediated by Th2-related cytokines, such as interleukin-4 (IL-4) and IL-5.

This aspect of the invention, therefore, in one embodiment relates to the use of retinoid antagonists, their pharmaceutically acceptable salts or pharmaceutically acceptable hydrolyzable esters, for the manufacture of a medicament for the treatment of T-helper cell

type 2 (Th2)-mediated immune diseases. In another embodiment this aspect of the invention relates to the use of retinoid antagonists, their pharmaceutically acceptable salts or pharmaceutically acceptable esters thereof for the manufacture of a medicament for the treatment of disease mediated by Th2-related cytokines, such as IL-4 and IL-5. In this respect the invention more particularly relates to a method for treating patients having T-helper cell type 2 (Th2)- mediated immune diseases comprising administering to said human patient a compound selected from the group of retinoid antagonists, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, said compound being administered in an amount effective to treat said disease.

10 The term „treatment“ or „treating“ includes preventive and/or therapeutic treatment.

As used herein, the term „T-helper cell type 2-mediated immune diseases“ relates to diseases involving immunoglobulin E (IgE) and mast cells due to the development and activation of allergen-specific Th2 cells and it encompasses allergic diseases, such as atopic dermatitis, other dermatological diseases associated with atopy; allergic rhinitis or hay fever, allergic bronchial asthma in its acute or chronic, mild or severe forms, with or without acute or chronic bronchitis. Elevated serum levels of immunoglobulin E (IgE) and hypereosinophilia can be associated with these diseases. Retinoid antagonists are effective in all those immune diseases which are linked with an increase of Th2 cell activity and an increased secretion of the related cytokines, such as IL-4 and IL-5. The therapeutic effect of retinoid antagonists is supposedly due to a decrease in Th2 cell activity, a decreased secretion of the related cytokines, such as IL-4 and IL-5, and/or an increase in Th1 cell activity due to the enhancement of IL-12 production by activated myelomonocytic cells. [S. Romagnani, Ann. Rev. Immunol. 12, 227-257 (1994); Romagnani, ed., Th1 and Th2 Cells in Health and Disease. Chem. Immunol., Karger, Basel, 63, pp. 187-203 (1996); Abbas et al., Nature 383, 787-793 (1996)].

The efficacy of the retinoid antagonists in accordance with the present invention can be shown by their ability to either upregulate Th1 cell activity or induce/stimulate the production of cytokines, such as IL-12, IFN γ , TNF; and/or down-regulate Th2 cell activity, or inhibit the production of cytokines, such as IL-4 and IL-5 (see Examples 4 and 5 below).

30 Retinoid antagonists are active in the treatment of allergic bronchial asthma. The hallmarks of inflammation associated with asthmatic disease are the presence of activated eosinophils, an increased sensitivity of the airways (hyperresponsiveness), edema, mucus hypersecretion and cough. This inflammatory process is mediated by the generation and activation of Th2-type cells. The ability of retinoid antagonists to promote a Th1-type

response and thereby to suppress the Th2-type response is thought to be the mechanism underlying the efficacy of these compounds in allergic lung inflammation/asthma. Retinoid antagonists are acting on Th1-type cells, in inhibiting the signs and symptoms of allergic lung inflammation/asthma [Gavett et al., J. exp. Med. 182, 1527-1536 (1995); Kips et al.,
5 Am. J. Respir. Crit. Care Med. 153, 535-539 (1996)]. They are active in antigen/allergen (e.g. ovalbumin)-sensitized and challenged animals. Retinoid antagonists, given either systemically or topically by aerosol, are efficacious in attenuating, inhibiting or reversing bronchoconstriction, airway edema and mucus hypersecretion, airway inflammation, accumulation of eosinophils and neutrophils in the broncho-alveolar tissue and broncho-
10 alveolar lavage respectively, as well as airway hyperresponsiveness to non-specific stimuli (see Example 6 below).

For the treatment, the active compound, i.e. a retinoid antagonist, a pharmaceutically acceptable salt or a pharmaceutically acceptable hydrolyzable ester thereof, is administered either systemically or topically. Preferably, said compound is administered as a
15 composition containing said active compound and a pharmaceutically acceptable carrier or diluent compatible with said active compound. In preparing such composition, any conventional pharmaceutically acceptable carrier can be utilized. When the drug is administered orally, it is generally administered at regular intervals, conveniently at mealtimes or once daily. It has been established that this compound is effective in doses
20 which show no or only mild side effects when given orally or when given topically. Therefore, oral or topical administration of the active compound is generally preferred. For treating diseases of the skin, mouth, nose, pharynx, larynx, bronchus etc. oral combined with topical administration may also be used advantageously.

In a third aspect of this invention, it has been found that administration of retinoid
25 antagonists, pharmaceutically acceptable salts, and pharmaceutically acceptable hydrolyzable esters thereof, are efficacious in treating patients with osteoporosis.

The invention, therefore, in that aspect, relates to the use of retinoid antagonists, their pharmaceutically acceptable salts or pharmaceutically acceptable hydrolyzable esters, for the manufacture of a medicament for the treatment of osteoporosis.

30 Accordingly, the invention also relates to a method for treating patients having osteoporosis comprising administering to said human patient a compound selected from the group of retinoid antagonists, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, said compound being administered in an amount

effective to treat said disease. The term "treatment" or "treating" includes preventive and/or therapeutic treatment.

With reference to that aspect of the invention the term "retinoid antagonists" encompasses the groups a) to g) of compounds as defined earlier herein.

- 5 As used herein the term "osteoporosis" includes primary as well as secondary osteoporosis and relates to a disease characterized by a low bone mass and a micro-architectural deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in bone fracture risk.

10 The two most common forms of primary osteoporosis are: 1. The postmenopausal osteoporosis in women (osteoporosis type I) with a high rate of bone remodeling, also called high turnover form of osteoporosis. The increased resorption of trabecular bone leads most often to vertebral and wrist fractures. 2. Senile osteoporosis in individuals of both sexes mostly over 70 years (osteoporosis type II) with a low rate of bone remodeling called low turnover form of osteoporosis. The increased resorption of both trabecular and
15 cortical bone leads frequently to fractures of vertebrae and femoral neck.

Secondary osteoporosis is related to many conditions such as diseases (e.g. rheumatoid arthritis, tumor-induced osteolysis with or without hypercalcemia, intestinal and renal disorders), immobilisation/lack of exercise, malnutrition, disorders of calcium
20 intake or vitamin D intake and their metabolism, disorders of parathyroid hormone metabolism, and drug therapy (e.g. corticosteroids, heparin).

The efficacy of retinoid antagonists in accordance with the present invention can be shown by their ability to influence bone remodeling, a process resulting from bone resorption and bone formation. Bone resorption is mainly accomplished by multinucleated osteoclasts endowed with specialized organelles and plasma membrane structures to allow
25 resorption of inorganic substances as well as organic matrix components. Bone formation is mainly a function of osteoblasts that build up the extracellular matrix consisting of proteoglycans, type I collagen, non-collagen proteins, osteonectin, osteocalcin and other components. A further function of osteoblasts is bone mineralization, involving induction of certain enzymes (e.g. alkaline phosphatase), incorporation of calcium and other
30 components into the inorganic bone structure, such as hydroxyapatite.

When bone resorption rate is higher than bone formation, it leads to a net reduction in bone mass, which occurs in osteoporosis. Retinoid antagonists decrease bone resorption

and/or increase bone formation and are therefore useful in prevention and therapy of osteoporosis.

Under physiological and pathological conditions a series of compounds are known to influence and particularly induce or stimulate bone resorption such as hormones, vitamins, growth factors, cytokines, prostaglandins, lipopolysaccharide etc. (Reviews are given in the book Principles of Bone Biology, Eds. J.B. Bilezikian et al., Academic Press, San Diego 1996: Horowitz MC et al., Local regulators of bone, pp. 687-700. Pilbeam CC et al., Prostaglandins and bone metabolism, pp. 715-728. Mundy GR, Role of cytokines, parathyroid hormone and growth factors in malignancy, pp. 827-836. Rodan GA et al., Pathophysiology of osteoporosis, pp. 979-990. Jones G, Pharmacological mechanism of therapeutics: Vitamin D and analogs, pp. 1069-1081. Hakeda et al., The growth and culture of bone cells: Osteoclastic, pp. 1217-1228. Geddes AD, Animal models of bone diseases, pp. 1343-1354).

The following compounds known as inducing/stimulating bone resorption were examined: Parathyroid hormone (PTH), parathyroid hormone related peptide (PTHrP), calcitriol (1,25-dihydroxyvitamin D₃), all-trans retinoic acid (all-trans RA), 9-cis retinoic acid (9-cis RA), prostaglandin E₂ (PGE₂), tumor necrosis factor α (TNF α), and interleukin-1 α (IL-1 α); Vaes G, Cellular biology and biological mechanism of bone resorption, Clinical Orthopaedics and related Research, 1988, 231, 239-271. Houghs S. et al., Effects of hypervitaminosis A on the bone and mineral metabolism of the rat, Endocrinology 1988, 122, 2933-2939. Tullberg-Reinert H. et al., Different inhibitory actions of cyclosporin A and cyclosporin A-acetate on lipopolysaccharide-, interleukin 1-, 1,25-dihydroxyvitamin D₃-, and parathyroid hormone-stimulated calcium and lysosomal enzyme release from mouse calvaria in vitro. Agents and Actions 1991, 32, 321-332. Ammann P. et al., Effects of the biphosphonate tiludronate on bone resorption, calcium balance and bone mineral density. J. Bone Miner. Res. 1993, 8, 1491-1498. Bonjour JP et al., Tiludronate: Bone pharmacology and safety. Bone 1995, 17, 473S-477S. Kindmark A et al., Inhibitory effects of 9-cis and all-trans retinoic acid on 1,25(OH)₂ vitamin D₃-induced bone resorption Calcif. Tissue Int. 1995, 57, 242-244. Saneshige S., Retinoic acid directly stimulates osteoclastic bone resorption and gene expression of cathepsinK/OC-2. Biochem. J. 1995, 309, 721-724.

It could be demonstrated that retinoid antagonists inhibit bone resorption induced by above mentioned resorption stimulating compounds. This was proven in the widely used model of neonatal mouse calvaria (skull bones) tissue culture, a model predictive for

agents useful in clinical prevention and therapy of osteoporosis e.g. biphosphonates. The experiments are described below in Example 7.

In a fourth aspect the present invention relates to the use of retinoid antagonists comprising retinoids with selective retinoic acid receptor (RAR) antagonist activity, retinoid X receptor (RXR) antagonistic activity, or mixed RAR-RXR antagonistic activity for use in the treatment of preneoplastic and neoplastic diseases such as precancerous lesions of the skin and mucous membranes, or solid tumors of skin, mucous membranes, head and neck, lung, stomach, colon, breast, ovary, cervix and prostate; and in the manufacture of a medicament for the treatment of such diseases (see Example 8 below).

For the treatment of the above-mentioned diseases, the active compound, i.e. a retinoid antagonist, a pharmaceutically acceptable salt or a pharmaceutically acceptable hydrolyzable ester thereof, is administered either systemically or topically. Preferably, said compound is administered as a composition containing said active compound and a pharmaceutically acceptable carrier or diluent compatible with said active compound. In preparing such composition, any conventional pharmaceutically acceptable carrier can be utilized. When the drug is administered orally, it is generally administered at regular intervals, conveniently at mealtimes or once daily. It has been established that this compound is effective in doses which show no or only mild side effects when given orally or when given topically. Therefore, oral or topical administration of the active compound is generally preferred. For treating diseases of the skin, mouth, nose, pharynx, larynx, bronchus etc. oral combined with topical administration may also be used advantageously.

In the treatment of the above-mentioned diseases, retinoid antagonists, when administered orally do not or only slightly induce the adverse events belonging to the toxic syndrome of hypervitaminosis A, such as mucocutaneous, musculoskeletal, neurologic manifestations and elevation of transaminases, triglycerides and cholesterol. In addition, they are not or less teratogenic in contrast to the receptor agonistic retinoids clinically useful in the treatment of dermatological and oncological diseases, such as all-trans retinoic acid (tretinoin), 13-cis retinoic acid (isotretinoin), etretinate and acitretin.

In the treatment of T-helper cell type 2-mediated immune diseases, retinoid antagonists, pharmaceutically acceptable salts or pharmaceutically acceptable hydrolyzable esters thereof, can be used alone or in combination with other measures, e.g. in combination with other pharmaceutically active substances such as topical or systemic corticosteroids, antihistaminics and bronchodilating agents. If used in combination with

other substances, retinoid antagonists and said other substances can be administered separately or incorporated in effective amounts into one pharmaceutical composition.

In the treatment of osteoporosis, retinoid antagonists, pharmaceutically acceptable salts or pharmaceutically acceptable hydrolyzable esters thereof, can be used alone or in combination with other measures, e.g. in combination with other pharmaceutically active substances such as calcium, vitamin D derivatives, estrogens, anabolics, calcitonin or biphosphonates. If used in combination with other substances, retinoid antagonists and said other substances can be administered separately or incorporated in effective amounts into one pharmaceutical composition.

In accordance with this invention the retinoid antagonists can also be administered in the form of its pharmaceutically acceptable hydrolyzable esters. Any pharmaceutically acceptable hydrolyzable ester can be used in the compositions and methods of this invention. Among the preferred esters are: the aromatic esters such as benzyl esters in which the benzyl moiety is unsubstituted or substituted with lower alkyl, halo, nitro, thio, or substituted thio; or lower alkyl esters, e.g. ethyl, t-butyl, cyclopentyl, cyclohexyl or cycloheptyl ester; or 9-fluorenylmethyl ester.

The aforementioned retinoid antagonists, the salts and esters thereof are useful especially in pharmaceutically acceptable oral or topical modes. These pharmaceutical compositions contain said active compound in association with a compatible pharmaceutically acceptable carrier material. Any conventional carrier material can be utilized. The carrier material can be organic or inorganic inert carrier material suitable for oral administration. Suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene-glycols, petroleum jelly and the like. Furthermore, the pharmaceutically active preparations may contain other pharmaceutically active agents. Additionally, additives such as flavouring agents, preservatives, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding.

The pharmaceutical preparations can be made up in any conventional form including inter alia: (a) a solid form for oral administration such as tablets, capsules (e.g. hard or soft gelatine capsules), pills, sachets, powders, granules, and the like; (b) preparations for topical administrations such as solutions, suspensions, ointments, creams, gels, micronized powders, sprays, aerosols and the like. The pharmaceutical preparations may be sterilized and/or may contain adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, salts for varying the osmotic pressure and/or buffers.

For topical administration to the skin or mucous membrane the aforementioned derivative is preferably prepared as ointments, tinctures, creams, gels, solution, lotions, sprays; aerosols and dry powder for inhalation, suspensions, shampoos, hair soaps, perfumes and the like. In fact, any conventional composition can be utilized in this invention. Among the preferred methods of applying the composition containing the agents of this invention is in the form of an ointment, gel, cream, lotion, spray; aerosol or dry powder for inhalation. The pharmaceutical preparation for topical administration to the skin can be prepared by mixing the aforementioned active ingredient with non-toxic, therapeutically inert, solid or liquid carriers customarily used in such preparation. These preparations generally contain 0.01 to 5.0 percent by weight, preferably 0.1 to 1.0 percent by weight, of the active ingredient, based on the total weight of the composition.

In preparing the topical preparations described above, additives such as preservatives, thickeners, perfumes and the like conventional in the art of pharmaceutical compounding of topical preparation can be used. In addition, conventional antioxidants or mixtures of conventional antioxidants can be incorporated into the topical preparations containing the aforementioned active agent. Among the conventional antioxidants which can be utilized in these preparations are included N-methyl- α -tocopherolamine, tocopherols, butylated hydroxyanisole, butylated hydroxytoluene, ethoxyquin and the like. Cream-base pharmaceutical formulations containing the active agent, used in accordance with this invention, are composed of aqueous emulsions containing a fatty acid alcohol, semi-solid petroleum hydrocarbon, ethylene glycol and an emulsifying agent.

Ointment formulations containing the active agent in accordance with this invention comprise admixtures of a semi-solid petroleum hydrocarbon with a solvent dispersion of the active material. Cream compositions containing the active ingredient for use in this invention preferably comprise emulsions formed from a water phase of a humectant, a viscosity stabilizer and water, an oil phase of a fatty acid alcohol, a semi-solid petroleum hydrocarbon and an emulsifying agent and a phase containing the active agent dispersed in an aqueous stabilizer-buffer solution. Stabilizers may be added to the topical preparation. Any conventional stabilizer can be utilized in accordance with this invention. In the oil phase, fatty acid alcohol components function as a stabilizer. These fatty acid alcohol components function as a stabilizer. These fatty acid alcohol components are derived from the reduction of a long-chain saturated fatty acid containing at least 14 carbon atoms. Also, conventional perfumes and lotions generally utilized in topical preparation for the hair can be utilized in accordance with this invention. Furthermore, if desired, conventional emulsifying agents can be utilized in the topical preparations of this invention.

For topical treatment of allergic rhinitis and allergic bronchial asthma nasal and inhalation aerosols are used. Formulations for such aerosols are described in Drugs and Pharmaceutical Sciences, Marcel Dekker, New York, 1996, Vol. 72, pp. 547-574.

Furthermore, the active compound can be delivered by dry powder inhalation. Such formulations and devices are described in Pharmaceutical Technology, June 1997, pp. 117-125.

A preferred oral dosage form comprises tablets, pills, sachets, or capsules of hard or soft gelatin, methylcellulose or of another suitable material easily dissolved in the digestive tract. Each tablet, pill, sachet or capsule can preferably contain from about 5 to about 200 mg, more preferably from about 20 to about 100 mg, of active ingredient. The oral dosages contemplated in accordance with the present invention will vary in accordance with the needs of the individual patient as determined by the prescribing physician. Generally, however, a daily dosage of from 0.05 to 20 mg per kg of body weight, preferably 0.1 to 7 mg, and most preferably from about 0.3 mg to about 1.5 mg per kg of body weight of the patient is utilized. This dosage may be administered according to any dosage schedule determined by the physician in accordance with the requirements of the patient.

The dosage for treatment typically depends on the route of administration, the age, weight and disease condition of the individual. Suitable dosage forms are known in the art or can be easily obtained in a manner known per se. Formulations of lotions, gels, creams, sprays; aerosols and dry powder for inhalation, hard or soft gelatin capsules, tablets and sachets that are particularly suitable in the scope of the present invention or that can be easily adjusted in accordance with the above teaching are in the art.

The pharmacological activity of the retinoid antagonists as disclosed above can be demonstrated in various test models as shown below in Examples 1-8. In Examples 1-8 the following compounds were used:

Compound A: (2E,4E,6Z)-7-[3,5-di-tert.butyl-2-ethoxyphenyl]-3-methyl-2,4,6-octatrienoic acid

Compound B: (2E,4E,6Z)-7-[3,5-di-tert.butyl-2-butyloxyphenyl]-3-methyl-2,4,6-octatrienoic acid

Compound C: all-trans retinoic acid

Compound D: 13-cis retinoic acid

Compound E: 9-cis retinoic acid

Compound F: 4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalene-carboxamido)benzoic acid

Compound G: (2E,4E)-3-methyl-5-[(1S,2S)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid

Compound H: p-[(E)-2-[3',4'-Dihydro-4',4'-dimethyl-7'-(heptyloxy)-2'H-1-benzothiopyran-6'-yl]propenyl]benzoic acid 1',1'-dioxide

5 Compound I: 4-(7,7,10,10-Tetramethyl-1-pyridin-3-ylmethyl-4,5,7,8,9,10-hexahydro-1H-naphto[2,3-g]indol-3-yl)-benzoic acid

Example 1

10 Effect of retinoids with RXR antagonistic activity on weight loss induced by all-trans retinoic acid in mice.

The test compounds were solubilized/suspended in arachis oil and applied intraperitoneally into female mice (25/30 g) for 5 days a week during 2 weeks. The results are shown in Table 1.

15 Table 1

Compound/ Dose [mg/kg]	C/200	C/200 + A/200	C/100	C/100 + A/200	A/200
	n=2	n=2	n=10	n=2	n=2
% survival after 14 days	0	100	20	100	100
% weight change after 4 days	-38	-23	-18	-13	+15
% weight change after 7 days	dead	-23	-29	-8	+26

Example 2

20 Suppressive effect on skin irritation caused by all-trans retinoic acid in hairless rats.

The animals were treated epicutaneously (0.025 ml/2 cm²) once a day, 5 days a week (Monday to Friday) for 4 consecutive weeks with the mixed solution of the test compounds in acetone/ethanol (1/1).

25 The animals were observed daily, Monday to Friday, for signs of erythema and oedema on each individual test site, starting at approximately 24 hours after initiating the study.

The intensity of all skin reactions induced was recorded in the raw data sheets according to the following grading scale:

- 0 = No skin reactions
- 1 = Slight skin reactions (slight to defined erythema)
- 5 2 = Well defined reaction (well defined to marked erythema)
- 3 = Moderate skin reaction (moderate to marked erythema with defined oedema)
- 4 = Severe skin reaction (severe to strong erythema and marked oedema)

The mean cumulative skin irritation scores calculated after each treatment application are presented in Figures 1 and 2.

10

Example 3

Suppressive effect on the in vitro teratogenic activity of various retinoids.

Fore- and hindlimb buds of day 13 rat embryos were dissociated in calcium-magnesium-free balanced salt solution containing 0.1% trypsin and 0.1% EDTA at 37°C. The cell density was adjusted to 2×10^7 limb bud cells/ml in CMRL medium containing 10% NU-serum. High cell density cultures were set up by dispensing 20 μ l of the cell suspension as a discrete drop in the center of each well of a 24-well dish. The cells were allowed to attach for 1-2 h at 37°C before the cultures were flooded with the appropriate culture medium. The test substances then were dissolved in dimethylsulfoxide and added at the same time on day 1 of culture. An equivalent amount of the solvent (0.4%) was added to the control cultures. After 7 days in culture the grade of differentiation of mesenchymal cells into chondrocytes, producing cartilage was determined by staining proteoglycans with alcian blue. The bound dye was extracted with 4 M guanidine hydro-chloride and the absorbance at 600 nm was determined spectrophotometrically.

Figure 3 shows the interaction of variable concentrations of Compound A with a constant concentration of all-trans retinoic acid (Compound C). C was kept during the experiment at a constant concentration of 1×10^{-6} mol/l. The concentrations of Compound A increased from 1×10^{-9} mol/l to 2×10^{-6} mol/l. The differentiation of the mesenchymal cells increased from about 5% to about 30% with increasing concentrations of Compound A.

Figure 4 shows the interaction of variable concentrations of Compound A (1×10^{-2} mol/l to 2×10^{-6} mol/l) with Compound D which was kept during incubation at the constant concentration of 1×10^{-6} mol/l. The differentiation of the mesenchymal cells increased from about 30% to about 70% with increasing concentrations of Compound A.

5 Figure 5 shows the interaction of variable concentrations of Compound A (1×10^{-9} mol/l up to 2×10^{-6} mol/l) with Compound E, which was kept during incubation at the constant concentration of 5×10^{-7} mol/l. The differentiation of the mesenchymal cells increased from about 5% to about 80% with increasing concentrations of Compound A.

10 Figure 6 shows the interaction of variable concentrations of Compound A (1×10^{-9} mol/l up to 2×10^{-6} mol/l) with Compound F which was kept during incubation at the constant concentration of 1×10^{-8} mol/l. The differentiation of the mesenchymal cells increased from about 5% to about 75% with increasing concentrations of Compound A.

15 Figure 7 shows the interaction of variable concentrations of Compound A (1×10^{-9} mol/l up to 2×10^{-6} mol/l) with Compound G, which was kept during incubation at the constant concentration of 1×10^{-6} mol/l. The differentiation of the mesenchymal cells increased from about 5% to about 110% with increasing concentrations of Compound A.

Example 4

In vitro assay for induction of IL-12 production by retinoid antagonists

20 THP-1 cells were obtained from American Tissue Culture Collection and cultured in complete medium. To assay for IL-12 production, THP-1 cells, 1.25×10^6 cells/ml, were stimulated with *S. aureus* Cowan strain (SAC) (1/1000) and human recombinant interferon- γ (huIFN- γ (1000 U/ml) [Ma et al., *J. Exp. Med.* 183, 147-157 (1996)]).

25 Alternatively, 0.5×10^6 human peripheral blood mononuclear cells (PBMC) (1 ml culture in 48 well plates) were primed with huIFN- γ (1000 U/ml) for 16 hours at 37°C, and then stimulated with SAC (1/1000). Supernatants were collected after 48 hours and freeze-dried at -20 °C until assayed [Panina-Bordignon et al., *J. Clin. Invest.* 100, 1513-1519 (1997)].

IL-12 production was measured by specific enzyme linked immuno sorbant assay (ELISA), using 20C2 antibody (rat anti human IL-12 heterodimer p40-p35), at 2.5 μ g/ml in coating buffer, and peroxidase-conjugated 4D6 antibody (rat anti human IL-12) at

250 ng/ml in assay buffer as described [Zhang et al., *J. Clin. Invest.* **93**, 1733-1739 (1994)]. Standard (recombinant human IL-12, 800 pg/ml to 6 pg/ml) and samples (100 µl) diluted in assay buffer were added to duplicate wells. Absorbance was read at 450-650 nm. The unknown IL-12 concentrations of the samples were read from the corresponding standard curve and multiplied by the corresponding dilution factor. Maximal IL-12 production varied between 200 and 400 pg/ml.

Lyophilized retinoid antagonists were diluted in DMSO under yellow light, on ice at a concentration of 2 mM. Serial dilutions (1 µM-1 pM) were prepared in complete RPMI medium. 10 µl of each dilution was added to 1 ml culture.

- 10 The results of the experiments indicate that the tested retinoid antagonists influence IL-12 production. In particular, the tested retinoid antagonists stimulate IL-12 production by activated human monocytes, see Table 2 and 3

Table 2

Retinoid antagonists specifically enhance IL-12 production by activated monocytes

	nM	IL-12 (pg/ml)	IL-10 (pg/ml)	TNF-α (pg/ml)
medium		0	<10	<10
SAC+IFN-γ		120	1040	1840
RAR α antagonist	1000	251	1343	1912
Compound H	100	102	1050	1600
	10	n.d.	1060	1392
medium		0	<10	<10
SAC+IFN-γ		126	1040	2000
RAR α,β,γ antagonist	1000	321	1116	2884
Compound I	100	205	983	2752
	10	173	971	2592
medium		0	<10	<10
SAC+IFN-γ		120	1040	1840
RXR antagonist	1000	298	1700	1560
Compound B	100	161	1521	1812
	10	106	1020	1484

Table 3

Retinoid antagonists enhance IL-12 production by PBMC and THP-1 cells that have been primed with IFN γ and stimulated with SAC

Compound	Receptor Specificity	Activity	Stimuli	Time * (hrs)	PBMC IL-12	THP-1 (pg/ml)
H	RAR α	antagonist	IFN γ +	0	503	306
			SAC	16	401	nd
I	RAR α, β, γ	antagonist	IFN γ +	0	371	364
			SAC	16	367	nd
B	RXR	antagonist	IFN γ +	0	568	577
			SAC	16	367	nd
none			none		<12	<2
			IFN γ +		360	275
			SAC			

- 5 * retinoid antagonists (1 μ g) were added at time 0 together with IFN γ or after 16 hours together with SAC.

Example 5

In vitro assay for inhibition of differentiation of human naive T cells into T helper 2 (Th2) cells by retinoid antagonists.

- 10 Naive T cells from cord blood were isolated and treated as described [Panina-Bordignon et al. *J. Clin. Invest.* 100, 1513-1519 (1997)]. Briefly, cord blood derived mononuclear cells were incubated with anti-CD45RA and anti-CD4 monoclonal antibodies. After a 20 minute incubation, cells were washed and incubated with goat anti-
- 15 mouse Ig-coated magnetic beads. Positive cells were separated and seeded at 1×10^6 cells/ml in a 24 well plate, together with autologous adherent cells, PHA, and IL-4 in the presence or absence of Compound H or Compound B at 1mM for 5 days. Cells were then washed and put back in culture in the presence of IL-2 (100 U/ml). After 10 days, the cells were collected and restimulated with PMA (50 ng/ml) and ionomycin (1 μ g/ml) for 4 hours.
- 20 Brefeldin A (10 μ g/ml) was added for the last 2 hours. Then the cells were fixed with 4% paraformaldehyde and permeabilized with saponin. Fixed cells were stained with FITC-anti IFN γ and PE-anti-IL-4mAbs and subjected to cytofluorimetric analysis.

The results of the experiment indicate that the tested retinoid antagonists reduce the differentiation of naive T cells into IL-4-secreting Th2 cells. (Table 4)

Table 4

Suppression of IL-4 expression in Th2 cells by retinoid antagonists

	IL-4 expressing cells	
	% gated cells	% Th2 cells
Th2	26.32	100
Th2 + Compound H	10.8	41
Th2 + Compound B	8.5	32

5

Example 6

Murine model of allergen-induced airway inflammation and hyperresponsiveness.

C57BL/6 mice (8-9 weeks old) are actively sensitized to ovalbumin (OA) on day 0 and on day 14 by a intraperitoneal injection of 10 µg OA + 1 mg Al(OH)₃ (gel suspension) in 0.2 ml sterile saline. On day 21, the mice were challenged with 5.0 % OA aerosol for 18 minutes. The aerosol is generated by a De Vilbiss Ultra-Neb 90 ultrasonic nebulizer, the outlet of which is connected to a small plexiglass chamber containing the animals. The mice are dosed with the RXR antagonist Compound B (10 and 30 mg/kg intraperitoneally) daily for three days, 48 hours, 24 hours, and immediately prior to OA challenge. Animals are used on day 21.

10

15

Airway Inflammatory Cell Accumulation: On day 24, three days after the challenge with OA aerosol, animals are anesthetized with urethane (2.4 g/kg) and tracheotomized with a 23 gauge catheter. Lungs are lavaged with aliquots (2 x 1 ml) of sterile Hank's balanced salt solution without Ca⁺⁺ and Mg⁺⁺. Lavage fluid is recovered after 30 sec by gentle aspiration and pooled for each animal. Samples then are centrifuged at 2000 rpm for 15 minutes at 5 °C. Red blood cells are lysed from the resulting pellet with 0.5 ml distilled water and the cells remaining in the pellet are reconstituted with 5 ml HBSS. Samples are centrifuged a second time at 2000 rpm for 15 minutes at 5 °C. The resulting pellet is suspended in 1 ml of HBSS. Total cell number is determined from an aliquot of the cell suspension using a hemocytometer. For cytological preparations, the cells are fixed on cytocentrifuged slides stained with a modified Wright's stain. Differential counts on at least 300 cells are made using standard morphological criteria to classify cells.

20

25

The results of the experiments indicate that the tested retinoid antagonists inhibit the allergen-induced accumulation of airway inflammatory cells (Table 5)

Table 5

Suppression of airway inflammatory cell accumulation by retinoid antagonists in a mouse model of allergen-induced airway inflammation

	Cell Influx (cells/ml)			Percent of reduction	
	Vehicle	Compound B		Compound B	
		10 mg/kg	30 mg/kg	10 mg/kg	30 mg/kg
Total leukocytes	795000	488000	271000	39%	66%
Macrophages	443000	289000	172000	35%	62%
Eosinophils	335000	176000	91000	48%	73%

Airway Hyperresponsiveness

On day 24, three days after the challenge with OA aerosol, animals are anesthetized with pentobarbital sodium (100 mg/kg, i.p.) and tracheotomized (PE-190). A jugular vein is cannulated with a sylastic tubing for i.v. drug delivery. Animals are placed in a whole body plethysmograph with a built-in pneumotachograph and mechanically ventilated ($V_f = 150/\text{min.}$, $V_t = 0.3\text{ml}$; Model 683, Harvard Apparatus, S. Natic, MA) immediately following pancuronium bromide (0.1 mg/kg, i.v.) treatment. Tidal volume is obtained from an integration of the respiratory flow signal using a differential pressure transducer (Validyne DP 103-08, Northridge, CA). Transpulmonary pressure is measured with a differential pressure transducer (Validyne DP 45-30, Northridge, CA) as the difference between intratracheal pressure and intrapleural pressure (obtained from a cannula inserted into the intercostal space). Changes in lung resistance ($\text{cm H}_2\text{O} / \text{ml} / \text{s}$) to increasing doses of methacholine (30, 100, 300, 1000 $\mu\text{g/kg}$, i.v.) are calculated from transpulmonary pressure, tidal volume, and respiratory flow measurements using a Modular Instrument Signal Processing System (Malvern, PA).

The results of the experiments indicate that retinoid antagonists can prevent or reverse allergic airway inflammation and inhibit antigen-induced bronchoconstriction, typical for allergic airway diseases, such as allergic bronchial asthma.

Example 7Examples for the Effect of Retinoid Antagonists on Bone Resorption.

Bone Resorption Assay

A series of agents are known to induce or stimulate bone resorption. In this assay
5 retinoid antagonists were tested for their capacity to inhibit or counteract the bone
resorptive activity of bone resorption inducers.

Material and Methods.

Bone resorption was determined by quantification of calcium release from neonatal
mouse calvaria (skull bones) in a tissue culture system, into supernatant medium. Calvaria
10 were prepared from 4 days old mice (body weight 4-4.5 g) of time controlled mated Swiss
albino mice. Frontal and parietal calvarial parts were dissected under a stereo-microscope
and halved along the median suture. Half calvaria from all animals were randomly
distributed to 6-well culture dishes (NUNC), containing stainless steel grids to support the
bones at the interface of gas and medium. The tissue is incubated in BGJ medium
15 (Bioconcept, Switzerland) according to a specified formulation supplemented with
1 mg/ml BSA (bovine serum albumin, SIGMA). Calvaria were cultured at 37°C in
humidified atmosphere of 5% CO₂ and 95% air. After 24 hours of preincubation, they were
transferred to new dishes containing 1.7 ml fresh medium and test substances. Bone
resorption inducers and retinoid antagonists were tested either as single agents or in
20 combination. The cultures were then run for 72 hours.

Calcium concentrations in culture supernatants were measured immediately after each
incubation period. Stable, free calcium was determined in 25 µl samples with a
spectrophotometric method using a methylthymol blue containing kit (Biomérieux), (E.M.
Gindler and J.D. King, Am. J. Clin. Pathol. 1972, 58, 376-382). The resorptive response was
25 expressed as µg calcium released per half calvarium during 3 days treatment.

Additional tests were done to examine calcium remaining in the calvaria. Calcium
was extracted with 5% trichloroacetic acid (TCA) and determined in 50 µl samples after
neutralization with NaOH. Furthermore, bone tissue viability was determined to exclude
cytotoxicity. This was quantified by the colorimetric MTT tetrazolium test (T. Mosmann, J.
30 Immunol. Methods 1983, 65, 55-63).

In these test, retinoid antagonists H and B were used.

The following bone resorption inducing/stimulating agents were used:

Calcitriol (1,25-dihydroxyvitamin D₃),

all-trans retinoic acid (all-trans RA), and

9-cis retinoic acid (9-cis RA), were synthesized by Roche Laboratories Basel.

5 Prostaglandin E2 (PGE2), cell culture tested (Sigma Chem. Co.),

Tumor necrosis factor α (TNF α), murine recombinant, and

Interleukin-1 α (IL-1 α), murine recombinant (Calbiochem.).

Bone resorption induced by the various agents was determined by measuring the amount of calcium released from half calvaria into the supernatant medium. Calcium
10 release is indicated in μg per half calvarium in 1.7 ml medium. Calcium release from calvaria into medium as well as uptake of calcium from medium into calvaria can be measured. Efficacy of retinoid antagonists to inhibit the activity of bone resorption inducers is expressed as % inhibition. It is calculated from the difference between the amount of released calcium by bone resorption inducers alone and the amount of released
15 calcium by their combination with retinoid antagonists. Retinoid antagonists alone induce neither calcium release nor uptake. Basal resorption rate in vehicle controls was 5 or less than 5%.

Results.

The results of the experiments (tables 6 to 11) demonstrate that retinoid antagonists
20 H and B counteract bone resorption induced by six different agents. These latter are considered to contribute to bone resorption responsible for osteoporosis and bone fractures in mammals and human beings. As can be seen from tables 6 to 11, all six bone resorbing agents induced a dose dependent calcium release from calvaria bone into the supernatant medium. Retinoid antagonists were able to inhibit calcium release induced by
25 these six different bone resorbing agents.

Inhibition of bone resorption by retinoid antagonists
Table 6: Calcitriol as inducing agent

Bone resorption inducer Calcitriol (nM)	Retinoid antagonist		Calcium release per half calvarium		Inhibition of bone resorption by retinoid antagonists	
	H (μ M)	B (μ M)	H	B	H	B
3	-	-	13 \pm 3		-	-
1	-	-	9 \pm 4		-	-
0.3	-	-	4 \pm 3		-	-
3	1	-	11 \pm 6		15.4	-
1	1	-	4 \pm 3		55.6	-
0.3	1	-	0 \pm 3		100	-
3	-	1		4 \pm 4	-	69.2
1	-	1		5 \pm 3	-	44.4
0.3	-	1		-1 \pm 2	-	125

Table 7: All-trans Retinoic Acid as inducing agent

Bone resorption inducer all-trans RA (μ M)	Retinoid antagonist		Calcium release per half calvarium (μ g)		Inhibition of bone resorption by retinoid antagonist (%)	
	H (μ M)	B (μ M)	H	B	H	B
1	-	-	23 \pm 8	17 \pm 3	-	-
0.1	-	-	19 \pm 11	13 \pm 3	-	-
0.01	-	-	1 \pm 4	1 \pm 2	-	-
1	10	-	-2 \pm 3		108.7	
0.1	10	-	-5 \pm 4		126.3	
0.1	1	-	2 \pm 11		89.5	
1	-	10		10 \pm 7		41.2
0.1	-	10		-3 \pm 4		123.1
0.1	-	1		5 \pm 4		61.5

Table 8: 9-cis Retinoic Acid as inducing agent

Bone resorption inducer 9-cis RA (μ M)	Retinoid antagonist		Calcium release per half calvarium (μ g)		Inhibition of bone resorption by retinoid antagonists (%)	
	H (μ M)	B (μ M)	H	B	H	B
1	-	-	40 \pm 11	18 \pm 4	-	-
0.1	-	-	22 \pm 8	17 \pm 10	-	-
0.01	-	-	6 \pm 10	3 \pm 3	-	-
1	10	-	28 \pm 7		30	
0.1	10	-	-5 \pm 3		123	
0.1	1	-	4 \pm 5		82	
1	-	10		-6 \pm 2		133.3
0.1	-	10		-4 \pm 3		123.5
0.1	-	1		2 \pm 5		33.3

Table 9: Prostaglandin E2 (PGE2) as inducing agent

Bone resorption inducer PGE2 (μ M)	Retinoid antagonist		Calcium release per half calvarium (μ g)		Inhibition of bone resorption by retinoid antagonists (%)	
	H (μ M)	B (μ M)	H	B	H	B
1	-	-	18 \pm 5	-	-	-
0.3	-	-	12 \pm 4	-	-	-
0.1	-	-	9 \pm 5	-	-	-
1	1	-	16 \pm 4	-	11.1	-
0.3	1	-	8 \pm 2	-	33.3	-
0.1	1	-	9 \pm 8	-	0	-
1	-	1	-	15 \pm 2	-	16.7
0.3	-	1	-	7 \pm 4	-	41.7
0.1	-	1	-	2 \pm 3	-	77.8

Table 10: Tumor Necrosis Factor α (TNF- α) as inducing agent

Bone resorption inducer TNF- α (ng/ml)	Retinoid antagonist		Calcium release per half calvarium (μ g)		Inhibition of bone resorption by retinoid antagonists (%)	
	H (μ M)	B (μ M)	H	B	H	B
100	-	-	24 \pm 3		-	-
30	-	-	18 \pm 8		-	-
10	-	-	3 \pm 4		-	-
100	1	-	20 \pm 4		16.7	
30	1	-	20 \pm 4		-11.1	
10	1	-	7 \pm 6		-133.3	
100	-	1		17 \pm 3		29.2
30	-	1		12 \pm 9		33.3
10	-	1		3 \pm 4		0

Table 11: Interleukin 1 α (IL-1 α) as inducing agent

Bone resorption inducer IL-1 α (nM)	Retinoid antagonist		Calcium release per half calvarium (μ g)		Inhibition of bone resorption by retinoid antagonists (%)	
	H (μ M)	B (μ M)	H	B	H	B
0.1	-	-	38 \pm 5		-	-
0.01	-	-	31 \pm 9		-	-
0.001	-	-	11 \pm 10		-	-
0.1	1	-	25 \pm 6		34.2	
0.01	1	-	24 \pm 10		19.4	
0.001	1	-	8 \pm 9		27.3	
0.1	-	1		28 \pm 8		26.3
0.01	-	1		26 \pm 5		16.1
0.001	-	1		12 \pm 6		-9.1

Example 8Efficacy of topical application of Compound B in the treatment of precancerous lesions of the skin (multiple actinic keratoses)


- 5 In a clinical trial, a cream containing 1 % of Compound B was applied on the lesions twice daily without occlusive dressing. The results are given in Table 12. As can be seen from Table 12, Compound B when administered topically is effective in the therapy of precancerous lesions of the skin and is – in contrast to other retinoids- well tolerated without inducing any irritation of
- 10 the lesions and the surrounding skin.

Table 12

Patient	Sex	Age (Years)	Localisation	Duration of Therapy	Reduction in Size of Lesions	Improvement	Adverse Events *
I	m	53	both forearms	4 months	50 %	marked	none
II	m	61	face	6 weeks	20 %	slight	none
III	f	69	face	4 months	30 %	moderate	none
IV	m	75	face and back of both hands	3 months	30 %	moderate	none
V	m	74	face	2 months	0 %	no	none


15 * particularly irritation of lesions and surrounding skin

- In accordance with the present invention the compounds of formula I can be
- 20 prepared by reacting a compound of formula XVIII



XVIII

with a compound of formula XIX





XIX

- 5 wherein A is formyl and B is di-(lower alkoxy)phosphinyl; R is lower alkoxy;
 and R¹, R² and R⁴ to R⁶ are as defined above;
 to yield a compound of formula I wherein R³ is lower alkoxy, and, if desired, hydrolysing
 the lower alkoxy group R³ in the so obtained compound of formula I.
- 10 The reaction of the compound XVIII with the compound XIX can be carried out
 according to methods which are known per se for the Horner (Wadsworth-Emmons)
 reaction. The reaction can be carried out in the presence of a base and, preferably, in the
 presence of an inert organic solvent, e.g. in the presence of sodium hydride in benzene,
 toluene, dimethylformamide, tetrahydrofuran, dioxane or a 1,2-dimethoxyalkane, or also a
 15 sodium alcoholate in an alkanol, e.g. sodium methylate in methanol, in a temperature
 range lying between 0° and the boiling point of the reaction mixture. Another example for
 a base which can be used in that reaction is lithium bis(trimethylsilyl)amide in an inert
 solvent like THF in a temperature range between -78°C and 0°C. A thus-obtained
 carboxylic acid ester of formula I can be hydrolyzed in a manner known per se, e.g. by
 20 treatment with alkalis, especially by treatment with aqueous-alcoholic sodium or potassium
 hydroxide solution in a temperature range lying between room temperature and the boiling
 point of the reaction mixture.

 The thus-obtained carboxylic acid of formula I can be isolated in a
 manner known per se as such or as a salt, e.g. as an alkali salt, especially as
 25 the Na or K salt.

 The compounds of formula XVIII are novel compounds and are also an object of the
 present invention. The compounds of formula XVIII can be prepared as set forth in
 Schemes 1 and 2 below:

Scheme 1

Scheme 2

Compounds of formula XVIII wherein the dotted bond is present, R¹ is lower alkyl- and R² is hydrogen can be obtained according to Scheme 1. In Scheme 1, compound (1) is converted to compound (2) by reaction with an organometallic nucleophile like an alkyl lithium or alkyl magnesium halogenide. Compound (2) can be oxidized to form
5 compound (3) by treatment with oxidizing agents such as manganese dioxide. Compound (3) can be converted to compound (4) in a Peterson olefination [Synthesis, 384 (1984) D.J. Ager, J. Org. Chem. 33, 780 (1968) D.J. Peterson] by reaction with ethyl trimethylsilyl acetate. The carboxylic ester group in compound (4) can be reduced to a hydroxy methyl group by treatment with a metal hydride such as diisobutyl aluminum hydride to give
10 compound (5) which can be oxidized by treatment with oxidizing agents such as manganese dioxide to give a compound of formula XVIII wherein R¹ is lower alkyl and R² is hydrogen.

Compounds of formula XVIII wherein the dotted bond is absent and R¹ and R² taken together are methylene can be obtained as set forth in Scheme 2. According to
15 Scheme 2, compound (6) is reacted with trimethylsilyl acetylene in the presence of tetrakis (triphenylphosphine) palladium(0) and CuI to yield compound (7) which, after removal of the trimethylsilyl group by treatment with tetrabutyl ammonium fluoride and formylation of the so-obtained compound (8) with dimethyl formamide in the presence of a base such as butyl lithium yields compound (9). The formyl group in compound (9) can be reduced
20 to the hydroxymethyl group by treatment with a metal hydride such as sodium borohydride in ethanol to give compound (10). Reduction of the triple bond in compound (10) e.g., by means of a Lindlar catalyst, affords compound (11) which is converted to compound (12) by a modified Simmons-Smith reaction [Tetrahedron 24, 53 (1968) J. Furukawa, N. Kawabata, J. Nishimura, J. Org. Chem. 42, 3031 (1977) N. Kawabata et al.].
25 This cyclopropanation can also be carried out in an enantioselective way according to the method of Fujisawa et al. (Chem. Letters, 61 (1992) using (R,R) or (S,S)-diethyltartrate as chiral auxiliary. Compound (12) can be oxidized using methods known in the art, e.g., by pyridinium chlorochromate, or by a Swern- or Dess-Martin oxidation to yield a compound of formula XVIII wherein A is formyl, the dotted bond is absent and R¹ and R² taken
30 together are methylene.

All these reactions can be carried out in a manner known per se.

The invention is illustrated further by the Examples which follow.

Example 9

4.0 g of 3,5-di-tert.-butyl-2-hydroxybenzaldehyde (CAS # 37942-07-7) was dissolved in dimethylformamide (DMF). This was treated with 0.89 g of sodium hydride (50% in oil suspension) and stirred at 25°C until hydrogen was no longer evolved. To this was added 2.01 ml n-bromobutane and the mixture was heated to 85°C for 14 hr. This was cooled and poured into water. The aqueous was extracted with ether. The ether layer was washed with water, dried (MgSO₄), and solvent was removed. Purification was accomplished by florsil column chromatography (15% ether/hexane) to give 5.4 g of 3,5-di-tert.-butyl -2-butyloxybenzaldehyde; ¹H NMR (CDCl₃) δ 10.31 (s, 1H, aldehyde), 7.70 (dd, 4H, aromatics), 3.94 (t, 2H, -OCH₂-).

3.5 g of 3,5- di-tert.-butyl-2-butyloxybenzaldehyde was dissolved in 30 ml of ethyl ether and cooled with stirring to 0°C. 11.4 ml of methyl lithium (1.55M in ether) was added via syringe. This was stirred for 10 min. and poured into 1M ammonium chloride and shaken. The ether layer was separated, dried (Na₂SO₄), and solvent removed to give 3.7 g of an oil which was purified by chromatography (silica gel - 5% ether/hexane) to give 3.3 g of 1-(3,5- di-tert.-butyl-2-butyloxyphenyl)ethanol; ¹H NMR (CDCl₃) δ 7.34 (dd, 4H, aromatics), 5.25 (m, 1H, -CH₃CH-), 3.85 (t, 2H, -OCH₂-).

2.77 g (9 mmol) of 1-(3,5- di-tert.-butyl-2-butyloxyphenyl)ethanol was dissolved in 120 ml of toluene that had been treated with 14 g of manganese(IV)oxide. This was well stirred at 75°C for 5 hr. This was cooled and filtered through celite. Solvent was removed to give 2.27 g of 1-(3,5- di-tert.-butyl -2-butyloxyphenyl)ethanone. ¹H NMR (CDCl₃) δ 7.38 (dd, 4H, aromatics), 2.62 (s, 3H, CH₃C-), 3.72 (t, 2H, -OCH₂-).

1.43 g of diisopropylamine in 20 ml of tetrahydrofuran (THF) was treated with 8.4 ml of n-butyl lithium (1.6M in hexane) at -20°C. This was cooled to -78°C and treated with 2.26 g ethyl trimethylsilylacetate. This was allowed to warm to 0°C and poured into water and extracted into hexane. The extract was washed with water, dried (MgSO₄), and had solvent removed to give an oil. Purification and separation of isomers was accomplished by silica gel chromatography (15% ether/hexane) to give 3.5 of (Z)-3-(3,5-di-tert.-butyl -2-butyloxyphenyl)-butenoic acid ethyl ester. ¹H NMR (CDCl₃) δ 7.05 (dd, 4H, aromatics), 5.90 (s, 1H, 2-H), 3.96 (q, 2H, -OCH₂CH₃), 3.70 (t, 2H, -OCH₂-), 2.21 (s, 3H).

0.9 g of (E)-3-(3,5- di-tert.-butyl -2-butyloxyphenyl)-butenoic acid ethyl ester was dissolved in 20 ml of dry ether. This was cooled to -78°C and treated with 6.0 ml of diisobutylaluminum hydride (1.0M in hexane). The temperature was allowed to warm to 0°C and was then treated with 20% aqueous Rochelle salt. This was stirred at 25°C for 1 hr. The organic fraction was separated, washed with water, dried (Na₂SO₄), and had solvent removed to give 0.78 g of (Z)-3-(3,5- di-tert.-butyl -2-butyloxyphenyl)-buten-1-ol.

¹H NMR (CDCl₃) δ 7.08 (dd, 4H, aromatics), 5.90 (t, 1H, CH-OH), 3.80 (t, 2H, -OCH₂-), 2.49 (t, 1H, -OH), 2.21 (s, 3H).

0.66 g of (Z)-3-(3,5- di-tert.-butyl-2-butyloxyphenyl)-buten-1-ol was dissolved in 100 ml ether and cooled to 15°C. 6.6 g of manganese(IV)oxide slurried in 50 ml ether was added to the above solution. This was stirred at ambient for 3 hr. The mixture was filtered through celite and had the solvent removed. This gave 0.64 g of (Z)-3-(3,5- di-tert.-butyl -2-butyloxyphenyl)-buten-1-al. ¹H NMR (CDCl₃) δ 9.45 (d, 1H, aldehyde), 7.08 (dd, 4H, aromatics), 5.90 (t, 1H, CH-OH), 3.80 (t, 2H, -OCH₂-), 2.49 (t, 1H, -OH), 2.21 (s, 3H).

635 mg of triethyl-3-methyl-4-phosphonocrotonate (CAS # 41891-54-7) was dissolved in 5 ml THF, cooled to -78°C and treated with 2.2 ml (2.2 mmol) (1.0M in THF) of lithium bis(trimethylsilyl)amide. While at -78°C, 600 mg of (Z)-3-(3,5- di-tert.-butyl-2-butyloxyphenyl)-buten-1-al in 5 ml THF was slowly added. This was stirred at -78°C for 0.5 hr. and poured into dilute aqueous ammonium chloride. The product was extracted into hexane and the organic portion washed with water, dried (Na₂SO₄), and had the solvent removed to give a crude oil. Purification and isomer separation was accomplished by silica gel chromatography (3% ether/hexane) to give 540 mg of (2E,4E,6Z)-7-(3,5-di-tert.-butyl -2-butyloxyphenyl)-3,7-dimethyl-2,4,6-heptatrienoic acid ethyl ester.

¹H NMR (CDCl₃) δ 7.12 (dd, 4H, aromatics), 6.62 (dd, 1H, H-5), 6.20 (d, 1H, H-4), 6.18 (d, 1H, H-6), 4.15 (q, 3H, -OCH₂ CH₃), 3.7 (dt, 2H, -OCH₂-), 2.22 (s, 3H), 2.15 (s, 3H).

520 mg of (2E,4E,6Z)-7-(3,5-di-tert.-butyl -2-butyloxyphenyl)-3,7-dimethyl-2,4,6-heptatrienoic acid ethyl ester was suspended in 5 ml ethanol and treated with 5 ml 6N NaOH and refluxed for 1.5 hr. This was cooled and acidified to pH 3 with dilute HCl. The solid which precipitated was extracted into chloroform. The organic portion was washed with water, dried (Na₂SO₄), and had the solvent removed. This gave a solid which was crystallized from methylene chloride/hexane to give (2E,4E,6Z)-7-[3,5-di-tert.butyl-2-

butyloxyphenyl]-3-methyl-2,4,6-octatrienoic acid. ^1H NMR (CDCl_3) δ 7.08 (dd, 4H, aromatics), 6.65 (dd, 1H, H-5), 6.22 (d, 1H, H-4), 6.18 (d, 1H, H-6), 3.7 (dt, 2H, $-\text{OCH}_2-$), 2.24 (s, 3H), 2.15 (s, 3H). M.p. 148-151°C.

5 In analogy to the above procedure the following compounds were prepared:

(2E,4E,6Z)-7-[3,5-di-tert.butyl-2-methoxyphenyl]-3-methyl-2,4,6-octatrienoic acid, m.p. 208-211°C (from THF/hexane)

10 (2E,4E,6Z)-7-[3,5-di-tert.butyl-2-ethoxyphenyl]-3-methyl-2,4,6-octatrienoic acid, m.p. 165-167°C (from THF/hexane)

(2E,4E,6Z)-7-[3,5-di-tert.butyl-2-hexyloxyphenyl]-3-methyl-2,4,6-octatrienoic acid, m.p. 156-160°C (from ether/hexane)

(2E,4E,6Z)-7-[3,5-di-tert.butyl-2-octyloxyphenyl]-3-methyl-2,4,6-octatrienoic acid, m.p. 137-139°C (from hexane).

15

Example 10

A solution of 13 g of 2-bromo-4,6-di-tert.butyl-phenol in 100 ml of dimethylformamide (DMF) was added dropwise to a suspension of 2.2 g of sodium hydride (50% in mineral oil) in 100 ml of DMF at 0°C. The reaction mixture was stirred at room temperature until hydrogen was no longer evolved (ca. 1 h), cooled again to 0°C and treated with a solution of 22 g of ethyl iodide in 50 ml of DMF. After stirring for about 1 hour at room temperature, the reaction mixture was poured on icewater, extracted with ethyl acetate, washed (H_2O), dried (Na_2SO_4) and evaporated to give 13.5 g of 1-bromo-2-ethoxy-3,5-di-tert.butyl-benzene as white crystals, m.p. 55-56°C.

10.1 g of 1-bromo-2-ethoxy-3,5-di-tert.butyl-benzene were dissolved in 50 ml of piperidine. After the addition of 490 mg of tetrakis(triphenylphosphine)palladium(0), 96 mg of copper(I)iodide and 140 mg of triphenylphosphine, the reaction mixture was heated to 90°C under argon and slowly treated with 6.3 g of (trimethylsilyl)acetylene (ca. 2 hours). The reaction was kept for further 10 minutes at 90°C before this procedure was repeated using the same amount of reagents. The reaction mixture was heated for another hour to 90°C, then poured on icewater, acidified with 80 ml of concentrated hydrochloric acid, extracted with ethyl acetate, washed (H_2O), dried (Na_2SO_4) and evaporated. The resulting

oil was purified by chromatography (silica gel, hexane/2.5% ethyl acetate) to give 8.3 g of 3,5-di-tert.butyl-2-ethoxy-phenylethynyl)-trimethylsilane as a slightly yellow oil.

8.3 g of this oil were dissolved in 120 ml of tetrahydrofuran (THF) and treated with 6.03 g of tetrabutylammonium fluoride. After 1 hour of stirring at ambient temperature, the reaction mixture was poured on icewater, extracted with ether, washed (H₂O), dried (Na₂SO₄) and evaporated. Purification of the resulting brown oil by chromatography (silica gel, hexane) gave 4.2 g of 1,5-di-tert.butyl-2-ethoxy-3-ethynyl-benzene as colourless oil which crystallized in the refrigerator, m.p. 46-47°C. A small sample was sublimed in high vacuum and melted at 48-49°C.

4.1 g of this compound were dissolved in 45 ml of THF and treated with 11 ml of n-BuLi (1.6 molar in hexane) at -78°C. After 1 hour at -78°C the reaction mixture was treated with 12 ml of DMF, warmed to room temperature, stirred for 6 hours, poured on icewater, acidified with concentrated hydrochloric acid, extracted with ethyl acetate, washed (H₂O), dried (Na₂SO₄) and evaporated to give 5 g of a brown oil which was purified by chromatography (silica gel, hexane/2% ether). The combined pure fractions yielded 2.4 g of a slightly orange oil, which crystallized in the freezer, m.p. 55-57°C.

2.4 g of 3,5-di-tert.butyl-2-ethoxy-phenyl)-propynal were dissolved in 25 ml of ethanol and treated with 90 mg of sodium borohydride during 1.5 hours at 0°C. The reaction mixture was acidified with 6 ml of 2N hydrochloric acid, poured on icewater, extracted with ether, washed (H₂O), dried (Na₂SO₄) and evaporated. The resulting orange oil was purified by chromatography (silica gel, hexane:ethyl acetate = 9:1) and recrystallized from pentane to give 2.2 g of 3-(3,5-di-tert.butyl-2-ethoxy-phenyl)-prop-2-yn-1-ol as white crystals, m.p. 82-84°C.

2 g of this compound were dissolved in 350 ml of ethanol, treated with 100 mg of Lindlar-catalyst and hydrogenated at normal pressure for 7.5 hours. After 3, 5 and 6 hours, 100 mg each of fresh Lindlar-catalyst were added. The catalyst was filtered off and the reaction solution evaporated. The resulting residue was purified by medium pressure chromatography (silica gel, hexane:ether = 8:2) and gave after crystallisation from hexane 1.3 g of (Z)-3-(3,5-di-tert.butyl-2-ethoxy-phenyl)-prop-2-en-1-ol, mp. 93-94°C.

1.3 g of this compound were dissolved in 50 ml of methylene chloride and treated with 13.7 ml of diethylzinc (1M in hexane) at -5°C. After 15 minutes of stirring at 0°C, the

reaction mixture was cooled to -20°C, treated dropwise with 7.4 g of methylene iodide, stirred for 1 hour at 0°C and 1.5 hours at room temperature and re-cooled to 0°C. 50 ml of saturated, aqueous ammonium chloride were dropped slowly into the white suspension. The clear reaction mixture was poured onto ice/saturated ammonium chloride solution, extracted with ether, washed (H₂O), dried (Na₂SO₄) and evaporated. The semi-crystalline residue was chromatographed (silica gel, hexane:ethyl acetate = 9:1) and gave after recrystallisation from hexane 1.3 g of (1RS,2SR)-[2-(3,5-di-tert.butyl-2-ethoxy-phenyl)-cyclopropyl]-methanol as white crystals, m.p. 102-103°C.

1.02 g of oxalyl chloride were dissolved in 37 ml of CH₂Cl₂ and treated with 0.86 ml of dimethyl sulfoxide at -60°C. After shortly warming to -35°C, the reaction mixture was re-cooled to -60°C and treated with a solution of 1.2 g of (1RS,2SR)-[2-(3,5-di-tert.butyl-2-ethoxy-phenyl)-cyclopropyl]-methanol in 20 ml of CH₂Cl₂. After 15 minutes of stirring at -50°C, 1.7 ml of triethylamine were dropped in. The reaction mixture was stirred for 2 hours at room temperature, poured on icewater, extracted with ether, washed (H₂O), dried (Na₂SO₄) and evaporated. The crude material was purified by flash chromatography (silica gel, hexane:ethyl acetate = 9:1) and recrystallized from hexane to give 1.01 g of (1RS,2RS)-2-(3,5-di-tert.butyl-2-ethoxy-phenyl)-cyclopropanecarbaldehyde as white crystals, m.p. 96-97°C.

908 mg of triethyl 3-methyl-4-phosphonocrotonate were dissolved in 25 ml of THF and treated with 3.4 ml of lithium bis(trimethylsilyl)amide (1.0 molar in THF) at -78°C. After 0.5 hour, a solution of 800 mg of the above described aldehyde in 25 ml of THF was slowly added. The cooling bath was removed and the temperature allowed to warm to 0°C. After 1.5 hours at 0°C, the reaction mixture was poured on saturated, aqueous ammonium chloride, extracted with ether, washed (H₂O), dried (Na₂SO₄) and evaporated. The crude product was purified by flash chromatography (silica gel, hexane:ethyl acetate = 9:1) and medium pressure chromatography (silica gel, hexane/2% ethyl acetate) to give after recrystallisation from hexane/ethyl acetate 650 mg of (2E,4E)-(1RS,2RS)-5-[2-(3,5-di-tert.butyl-2-ethoxy-phenyl)-cyclopropyl]-3-methyl-penta-2,4-dienoic acid ethyl ester as white crystals, m.p. 129-130°C and 370 mg of (2Z,4E)-(1RS,2RS)-5-[2-(3,5-di-tert.butyl-2-ethoxy-phenyl)-cyclopropyl]-3-methyl-penta-2,4-dienoic acid ethyl ester, m.p. 123-126°C.

600 mg of the (2E,4E)-ester were dissolved in 20 ml of ethanol and treated with a solution of 840 mg of potassium hydroxide in 4 ml each of ethanol and water. After the addition of 10 ml of THF, the clear solution was warmed to 45-50°C for 7 hours, cooled to

room temperature, poured in ice/1N hydrochloric acid, extracted with ethyl acetate, washed (H₂O), dried (Na₂SO₄) and evaporated. The crude material was recrystallized from ethyl acetate to give 440 mg of (2E,4E)-(1RS,2RS)-5-[2-(3,5-di-tert.butyl-2-ethoxy-phenyl)-cyclopropyl]-3-methyl-penta-2,4-dienoic acid as white crystals, m.p. 200-202°C.

- 5 According to the same procedure 370 mg of the (2Z,4E)-ester were hydrolyzed to give 270 mg of (2Z,4E)-(1RS,2RS)-5-[2-(3,5-di-tert.butyl-2-ethoxy-phenyl)-cyclopropyl]-3-methyl-penta-2,4-dienoic acid, m.p. 169-174°C.

Example 11

10

In analogy to Example 2, (2E,4E)-(1RS,2RS)-5-[2-(3,5-di-tert.butyl-2-butoxy-phenyl)-cyclopropyl]-3-methyl-penta-2,4-dienoic acid, m.p. 175-178°C (hexane/ethyl acetate) was synthesized using 1-bromo-2-butoxy-3,5-di-tert.butyl-benzene as starting material.

15

The following Examples describe pharmaceutical formulations according to the invention:

Example 12

a) Fill mass for soft gelatin capsules

	Active compound	5.0-200.0 g
20	Oil *	1-3 parts
	Wax mixture **	1-5 parts
	Fill volume	1-6 minims

*natural vegetable oils, e.g. soy oil, peanut oil, and artificial glycerides

**composition of natural and artificial waxes or partially hydrogenated fats

25 b) 20 mg Soft Gelatin Capsules

	<u>Ingredients</u>	<u>mg/capsule</u>
	Active compound	20.000
	dl- α -Tocopherol	0.028
	Hydrogenated Castor Oil	4.200
30	Caprylic/Capric/Stearic Triglyceride (Synthetic Triglyceride)	56.000
	Triglyceride, Medium Chain	<u>199.772</u>
	Total 280.000 mg	

Example 13Hard Gelatine capsules containing 20 mg active substance:

Composition: One Capsule contains:

	Active compound	20.0 mg
5	Gelatine Bloom 30	70.0 mg
	Maltodextrin MD 05	108.0 mg
	dl- α -Tocopherol	2.0 mg
	Sodium ascorbate	10.0 mg
	Microcrystalline cellulose	48.0 mg
10	Magnesium stearate	2.0 mg
	(weight capsule content)	260.0 mg

Procedure:

- The active substance is wet milled in a solution of gelatine, maltodextrin, dl- α -Tocopherol and sodium ascorbate.
- The wet milled suspension is spray-dried.
- The spray-dried powder is mixed with microcrystalline cellulose and magnesium stearate.
- 260 mg each of this mixture are filled into hard gelatine capsules of suitable size and color.

20

Example 14Tablet containing 20 mg active substance:Tablet kernel:

	Active compound	20.0 mg
25	Anhydrous lactose	130.5 mg
	Microcrystalline Cellulose	80.0 mg
	dl- α -Tocopherol	2.0 mg
	Sodium ascorbate	10.0 mg
	Polyvinylpyrrolidone K30	5.0 mg
30	Magnesium stearate	2.5 mg
	(Kernel weight)	250.0 mg

Film coat:

	Hydroxypropyl methylcellulose	3.5 mg
	Polyethylenglycol 6000	0.8 mg

Talc	1.3 mg
Iron oxide, yellow	0.8 mg
Titanium dioxide	0.8 mg
(weight of the film)	7.4 mg

5 Procedure:

The compound is mixed with anhydrous lactose and microcrystalline cellulose.

The mixture is granulated in water with a solution/dispersion of polyvinylpyrrolidone, dl- α -Tocopherol and sodium ascorbate.

10 The granular material is mixed with magnesium stearate and afterwards pressed as kernels with 250 mg weight.

The kernels are film coated with a solution/suspension of above-mentioned compositions.

Example 15Sachet containing active substance

	Active compound	200.0 mg
15	Lactose, fine powder	990.0 mg
	Microcrystalline Cellulose	1250.0 mg
	Sodium Carboxymethyl cellulose	14.0 mg
	dl- α -Tocopherol	5.0 mg
	Sodium ascorbate	20.0 mg
20	Polyvinylpyrrolidone K30	10.0 mg
	Magnesium stearate	10.0 mg

Example 16Lotion (solution)

		preferred
	Active compound	0.1-2.0 g
	Propylene Glycol	5.00-20.00 g
	PEG-Glyceryl Cocoate *	0.00-20.00 g
	dl- α -Tocopherol	0.001-0.50 g
	Ascorbyl Palmitate	0.01-0.20 g
	Propyl Gallate	0.001-0.02 g
	Citric acid, anhydr. **	0.00-0.20 g
	Isopropanol ***	40.00-90.00 g
	Water, dem. ad	<u>100.00 g</u>
		<u>100.00 g</u> resp. ml

*or other tensides

**or other complexing agents e.g. EDTA

***or other alcohols e.g. Ethanol

5

Example 17Gelpreferred

	Active compound	0.1-2.0 g		
	Propylene Glycol	5.00-20.00 g	10.00 g	
10	PEG-Glyceryl Cocoate *	0.00-20.00 g	10.00 g	
	dl- α -Tocopherol	0.001-0.50 g	0.02 g	
	Ascorbyl Palmitate	0.01-0.20 g	0.10 g	
	Propyl Gallate	0.001-0.02 g	0.002 g	
	Citric acid, anhydr. **	0.00-0.20 g	0.01 g	
15	Isopropanol ***	40.00-90.00 g	50.00 g	
	HPMC ****	0.50-5.00 g	3.00 g	
	Preservative *****	q.s.	q.s.	
	Water, dem. ad	<u>100.00 g</u>	<u>100.00 g</u>	resp. ml
	* or other tensides			
20	** or other complexing agents e.g. EDTA			
	*** or other alcohols e.g. Ethanol			
	**** Hydroxypropyl Methylcellulose or other polymers e.g. neutralised Carbomer, Methyl Cellulose, Sodium Carboxymethylcellulose			
	***** Preservatives e.g., Paraben esters (methyl, ethyl, propyl, butyl).			
25	Sorbic Acid. Benzoic Acid			

Example 18Cream

		<u>preferred</u>	
5	Active compound	0.1-2.0 g	
	Glycerol	0.00-10.00 g	5.00 g
	Na ₂ EDTA	0.001-0.50 g	0.03 g
	Glycerides *	5.00-20.00 g	10.00 g
	Cetyl Alcohol	0.50-5.00 g	1.00 g
10	Stearyl Alcohol	0.50-5.00 g	1.00 g
	Glycerol mono Stearate	1.00-8.00 g	4.00 g
	Ceteareth **	0.50-5.00 g	2.00 g
	dl- α -Tocopherol	0.001-0.50 g	0.02 g
	Preservative ***	q.s.	q.s.
15	Water, dem. ad	<u>100.00 g</u>	<u>100.00 g</u>
	* e.g. Caprylic/Capric/Triglyceride, Caprylic/Capric/Linoleic Triglycerides, natural glycerides, as well as e.g. Propylene Glycol, Dicaprylate/Dicaprate and waxes, such as Stearyl, Stearate, Oleyl Oleate, Isopropyl Myristate		
20	**	Ceteareth 5-30, or other emulsifiers such as Polysorbate 20-80, Sorbitane esters of fatty acids, fatty acid esters of PEG.	
	***	Preservatives e.g., Paraben esters (methyl, ethyl, propyl, butyl). Sorbic Acid. Benzoic Acid	

25 Example 19Aerosol for inhalation, metered dose inhaler


	Active compound	0.5 % (0.1-2.0%)
	Sorbitantriolate	5 %
30	dl- α -Tocopherol	0.4%
	Propellant (mixture of Trichlorofluoromethane and Dichlorodifluoromethane)	94.1 %

Example 20Dry powder inhaler

5	Active compound	0.5 mg (0.1 mg - 2.0 mg)
	(jet-milled, spray-dried)	
	Lactose monohydrate	25 mg


Claims

1. Compounds of the formula I



- 5 wherein the dotted bond is optional; and, when the dotted bond is present, R¹ is lower alkyl and R² is hydrogen; and, when the dotted bond is absent, R¹ and R² taken together are methylene to form a cis-substituted cyclopropyl ring; R³ is hydroxy or lower alkoxy; R⁴ is alkyl or alkoxy; and R⁵ and R⁶ are, independently, a C₄₋₁₂ alkyl group or a mono- or polycyclic C₅₋₁₂-
 10 hydrocarbon group which are linked to the phenyl ring through a quaternary carbon atom,
 and pharmaceutically acceptable salts of carboxylic acids of formula I.

2. Compounds as in claim 1 of the formula



- 15 wherein R¹ is lower alkyl and R³ to R⁶ are as in claim 1;
 and pharmaceutically acceptable salts of carboxylic acids of formula Ia.

3. The compound of claim 2, (2E,4E,6Z)-7-[3,5-di-tert.butyl-2-ethoxyphenyl]-3-methyl-2,4,6-octatrienoic acid.

- 20 4. The compound of claim 2, (2E,4E,6Z)-7-[3,5-di-tert.butyl-2-butyloxyphenyl]-3-methyl-2,4,6-octatrienoic acid.

5. The compounds of claim 2,


(2E,4E,6Z)-7-[3,5-di-tert.butyl-2-butyloxyphenyl]-3-methyl-2,4,6-octatrienoic acid ethyl ester,

(2E,4E,6Z)-7-[3,5-di-tert.butyl-2-methoxyphenyl]-3-methyl-2,4,6-octatrienoic acid,

5 (2E,4E,6Z)-7-[3,5-di-tert.butyl-2-hexyloxyphenyl]-3-methyl-2,4,6-octatrienoic acid,

(2E,4E,6Z)-7-[3,5-di-tert.butyl-2-octyloxyphenyl]-3-methyl-2,4,6-octatrienoic acid.

6. Compounds as in claim 1, of the formula



Ib

10

wherein R³ to R⁶ are as in claim 1;
and pharmaceutically acceptable salts of carboxylic acids of formula Ib.

7. The compound of claim 6,


15 (2E,4E)-(1RS,2RS)-5-[2-(3,5-di-tert.butyl-2-ethoxy-phenyl)-cyclopropyl]-3-methyl-penta-2,4-dienoic acid ethyl ester,

(2E,4E)-(1RS,2RS)-5-[2-(3,5-di-tert.butyl-2-ethoxy-phenyl)-cyclopropyl]-3-methyl-penta-2,4-dienoic acid.

(2E,4E)-(1RS,2RS)-5-[2-(3,5-di-tert.butyl-2-butoxy-phenyl)-cyclopropyl]-3-methyl-penta-2,4-dienoic acid.

20

8. Compounds of formula



XVIII

wherein A is formyl; and R¹, R² and R⁴ to R⁶ are as defined in claim 1.

9. Pharmaceutical preparations, containing a compound of formula I of claim 1 or pharmaceutically acceptable salts of a carboxylic acid of formula I and usual pharmaceutical carrier materials.

5 10. The use of a retinoid antagonist for reducing or abolishing adverse events in patients receiving retinoid agonist treatment.

11. The use as in claim 10, wherein the retinoid agonist treatment is for acne, psoriasis or premalignant or malignant diseases.

10 12. The use of a retinoid antagonist for the treatment of T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases or for the treatment of diseases mediated by Th2-related cytokines such as IL-4 and IL-5.

13. The use as in claim 12 wherein the disease is atopic dermatitis, allergic rhinitis or allergic bronchial asthma.

14. The use of a retinoid antagonist for the treatment of osteoporosis.

15 15. The use as in claim 14 wherein the osteoporosis is postmenopausal osteoporosis, or senile osteoporosis in both sexes, or all forms of secondary osteoporosis.

16. The use of a retinoid antagonist for the treatment of preneoplastic or neoplastic diseases.

20 17. The use as in claim 16 wherein the preneoplastic disease is precancerous lesions of the skin and mucous membranes, and the neoplastic disease is solid tumors of skin, mucous membranes, head and neck, lung, stomach, colon, breast, ovary, cervix and prostate.

18. The use of compounds of formula I of claim 1 or pharmaceutically acceptable salts of a carboxylic acid of formula I in the manufacture of a medicament for reducing or abolishing adverse events in patients receiving retinoid agonist treatment.

25 19. The use as in claim 18, wherein the retinoid agonist treatment is for acne, psoriasis or premalignant or malignant diseases.

20. The use of a retinoid antagonist in the manufacture of a medicament for the treatment of T-helper cell type 2 (Th2)-mediated immune diseases, such as

immunoglobulin E (IgE)-mediated allergic diseases or for the treatment of diseases mediated by Th2-related cytokines such as IL-4 and IL-5.

21. The use as in claim 20 wherein the disease is atopic dermatitis, allergic rhinitis or allergic bronchial asthma.

5 22. The use of a retinoid antagonist in the manufacture of a medicament for the treatment of osteoporosis.

23. The use as in claim 22 wherein the osteoporosis is postmenopausal osteoporosis, senile osteoporosis of both sexes, or secondary osteoporosis.

10 24. The use of a retinoid antagonist in the manufacture of a medicament for the treatment of preneoplastic or neoplastic diseases.

25. The use as in claim 24 wherein the preneoplastic disease is precancerous lesions of the skin and mucous membranes, and the neoplastic disease is solid tumors of skin, mucous membranes, head and neck, lung, stomach, colon, breast, ovary, cervix and prostate.

15 26. The use as in any one of claims 10-25, wherein the retinoic acid antagonist is a compound of formula I as claimed in claim 1.

27. The use as in claim 26, wherein the compound of formula I is a compound of formula I c.

20 28. The use as in claim 27, wherein the compound of formula I c is (2E,4E)-(1RS,2RS)-5-[2-(3,5-di-tert.butyl-2-butoxy-phenyl)-cyclopropyl]-3-methyl-penta-2,4-dienoic acid.

29. The novel compounds, compositions and use as described hereinbefore.

Figure 1

Comparison of the mean skin irritation scores evoked by
0.05% of Compound C alone and combined with 2.5% of Compound B




Figure 2

Comparison of the mean skin irritation scores evoked by
0.1% of Compound C alone and combined with 2.5% of Compound B




Figure 3:




Figure 4:




Figure 5:




Figure 6:





Figure 7:



INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/01467

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C57/42 C07C59/64 C07C47/232 A61K31/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 20913 A (LIGAND PHARM INC) 11 July 1996 see page 9 - page 10; claim 1; examples 1-6	1-29
X	S.S. CANAN KOCH ET AL: "Identification of the first retinoid X receptor homodimer antagonist" J. MED. CHEM., vol. 39, no. 17, - 1996 pages 3229-3234, XP002030143 cited in the application see page 3229, left column; compounds 11 and 12 in scheme 1 and page 3232, left column, "Conclusions". -/--	1-29

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 June 1999

Date of mailing of the international search report

07/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Arias-Sanz, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/01467

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 705 167 A (BERNARDON JEAN-MICHEL ET AL) 6 January 1998 see column 1 - column 2 ---	1-29
A	WO 97 09297 A (ALLERGAN INC ;BEARD RICHARD L (US); DUONG TIEN T (US); JOHNSON ALA) 13 March 1997	1-9
X	see pages 1, lines 1-27; page 3, formula 1; and page 6, lines 1-29. -----	10-29

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/01467

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9620913 A	11-07-1996	US 5721103 A	24-02-1998
		AU 4643096 A	24-07-1996
		BR 9510414 A	19-05-1998
		CA 2208981 A	11-07-1996
		EP 0800503 A	15-10-1997
		JP 10511948 T	17-11-1998
		NO 973017 A	28-08-1998
US 5705167 A	06-01-1998	FR 2719041 A	27-10-1995
		AT 165332 T	15-05-1998
		AU 674269 B	12-12-1996
		AU 1651195 A	16-11-1995
		BR 9501614 A	23-04-1996
		CA 2147806 A	27-10-1995
		DE 69502130 D	28-05-1998
		DE 69502130 T	13-08-1998
		EP 0679628 A	02-11-1995
		ES 2119325 T	01-10-1998
		FI 951966 A	27-10-1995
		GR 3026700 T	31-07-1998
		HU 74013 A	28-10-1996
		JP 2653992 B	17-09-1997
		JP 8104653 A	23-04-1996
		NO 951543 A	27-10-1995
		NZ 270865 A	26-11-1996
WO 9709297 A	13-03-1997	PL 308342 A	30-10-1995
		ZA 9502973 A	19-12-1995
		US 5776699 A	07-07-1998
		AU 7235496 A	27-03-1997
		CA 2230672 A	13-03-1997
		CN 1209802 A	03-03-1999
		CZ 9800621 A	11-11-1998
		EP 0853610 A	22-07-1998
		NO 980880 A	27-04-1998
		PL 325249 A	06-07-1998
		US 5877207 A	02-03-1999